Nav: Home

Investigative report on FDA advisory panels from Science's news department

July 05, 2018

An investigative report from Charles Piller, a contributing correspondent in the News department at Science, uncovers little recognized and unpoliced potential conflicts of interest among those who serve on FDA advisory panels to review drugs are under-reported. Some members of such panels are later receiving significant payments from either the makers of drugs they previously reviewed, or from competitors. This is happening, Piller notes, despite the FDA's established system to identify possible financial conflicts of interest among those recruited for new drug advisory panels. Piller, for this investigation, analyzed records on the federal Open Payments website between 2013 and 2016. Among other findings, he reports that of 107 physician advisors who voted on FDA advisory committees during this time, 40 later took more than $10,000 from the makers of drugs, or from competing firms. As well, Open Payments suggests that 26 physician advisors gained more than $100,000 in post-hoc earnings or research support, Piller says. These potential conflicts of interest may be more widespread than commonly thought, his reporting - including through additional anecdotes -- suggests. In one such example, a physician was found to have received more than $200,000 dollars for accommodations, honoraria, and consulting from the maker of a drug he voted to recommend for approval, and from competing firms. Even though these payments might not be truly "quid-pro-quo," according to Vinay Prasad, an oncologist who also studies financial conflicts that exist in drug approvals, those asked to weigh in stand to gain tremendously in their further professional careers. "It's in their best interest to play nice with the companies." Pillar also found that the FDA may have missed or judged insignificant financial ties to the physicians had before their service on the advisory panels. The FDA's process for reviewing the financial interests among those asked to serve as advisers uses an honor system - one based solely on the disclosures by the members themselves - and it's nearly always hidden from the public view. Piller's investigation suggests that many conflicts of interest are falling through the cracks. (A second story looks at FDA staff members who leave the agency to work for companies whose drugs they once reviewed.) The FDA declined Piller's requests to comment.
-end-


American Association for the Advancement of Science

Related Drugs Articles:

Using drugs for different diseases than initially intended for
Thousands of drugs have the potential to be effective against other diseases than they were developed for.
Virtual development of real drugs
systemsDock is a new, free on-line resource that makes screening for drugs faster and more accurate.
Migraine drugs underused
New research shows that more migraines could be safely treated with drugs that are known to constrict blood vessels.
Why cancer drugs can't take the pressure
A major reason why cancer drugs fail is that they cannot penetrate the high-pressure environment of solid tumors.
Designing better drugs
A new strategy for engineering protein fusions -- to make specific cell-targeted drugs without side effects -- could enable a safer, more potent class of protein drugs.
Why synthetic drugs are as scary as you think (video)
Synthetic drugs such as 'bath salts,' 'K2' or 'Spice' have made unsettling headlines lately, with reports of violent, erratic behavior and deaths after people have used the substances.
Using old drugs to treat new viruses
A group of drugs already in everyday use to treat psychosis or depression may also be used to defeat deadly and emerging viruses, according to new research led by the University of Leeds.
'Metal' drugs to fight cancer
What is the mechanism of action of metal-based chemotherapy drugs (the most widely used for treating common cancers like testicular or ovarian cancer)?
Using superlatives in the media for cancer drugs
The use of superlatives to describe cancer drugs in news articles as 'breakthrough,' 'revolutionary,' 'miracle' or in other grandiose terms was common even when drugs were not yet approved, had no clinical data or not yet shown overall survival benefits, according to an article published online by JAMA Oncology.
Seeking a better way to design drugs
With a three-year, $346,000 award from the National Institutes of Health, a research team at Worcester Polytechnic Institute.

Related Drugs Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Jumpstarting Creativity
Our greatest breakthroughs and triumphs have one thing in common: creativity. But how do you ignite it? And how do you rekindle it? This hour, TED speakers explore ideas on jumpstarting creativity. Guests include economist Tim Harford, producer Helen Marriage, artificial intelligence researcher Steve Engels, and behavioral scientist Marily Oppezzo.
Now Playing: Science for the People

#524 The Human Network
What does a network of humans look like and how does it work? How does information spread? How do decisions and opinions spread? What gets distorted as it moves through the network and why? This week we dig into the ins and outs of human networks with Matthew Jackson, Professor of Economics at Stanford University and author of the book "The Human Network: How Your Social Position Determines Your Power, Beliefs, and Behaviours".